Translating results from organism studies to human risk involves understanding the differences in ADME (Absorption, Distribution, Metabolism, Excretion) processes between species. Physiologically based pharmacokinetic (PBPK) models and in vitro-in vivo extrapolation (IVIVE) are used to predict human responses. Uncertainties are addressed through safety factors and regulatory guidelines.
